Autoimmune Diseases — Systemic Overview

Systemic autoimmune diseases represent a complex group of disorders characterized by the immune system's aberrant response to self-antigens, resulting in chronic inflammation and multi-organ damage. These conditions affect multiple organ systems simultaneously and are distinguished from organ-specific autoimmune diseases by their widespread clinical manifestations and diverse autoantibody profiles.

The pathogenesis involves a breakdown of immune tolerance through both central and peripheral mechanisms. Central tolerance failure occurs in the thymus and bone marrow, where self-reactive T and B cells should normally undergo negative selection. Peripheral tolerance breakdown involves defects in regulatory T cells (Tregs), altered cytokine profiles, and molecular mimicry between foreign and self-antigens.

Key Pathophysiologic Mechanisms:

• Type II Hypersensitivity: Antibody-mediated cytotoxicity (e.g., anti-dsDNA causing glomerulonephritis)
• Type III Hypersensitivity: Immune complex deposition leading to complement activation and tissue damage
• Type IV Hypersensitivity: T cell-mediated tissue destruction

The clinical presentation typically involves relapsing-remitting courses with periods of disease activity (flares) and remission. Common systemic features include fatigue, fever, weight loss, and arthralgias. The diagnosis requires integration of clinical findings, laboratory markers, and imaging studies, often utilizing classification criteria developed by international rheumatology societies.

Environmental and Genetic Factors: Genetic susceptibility is strongly associated with specific HLA alleles (particularly HLA-DR and HLA-DQ). Environmental triggers include viral infections (EBV, CMV), ultraviolet light exposure, certain medications, and hormonal factors. The female predominance (8:1 ratio in SLE) suggests hormonal influences, particularly estrogen's role in enhancing B cell activity and antibody production.

Early recognition and treatment are crucial for preventing irreversible organ damage and improving long-term outcomes. The therapeutic approach typically involves immunosuppression with corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologics targeting specific inflammatory pathways.

SLE is the prototype systemic autoimmune disease, characterized by the production of multiple autoantibodies and immune complex-mediated organ damage. The disease predominantly affects women of childbearing age (20-40 years) with significant ethnic variation in prevalence and severity.

Clinical Manifestations by System:

Diagnostic Laboratory Findings:

Autoantibodies in SLE:

• ANA (Antinuclear Antibodies): Positive in >95% of cases, typically homogeneous or speckled pattern
• Anti-dsDNA: Highly specific (95%), correlates with disease activity and nephritis risk
• Anti-Sm (Smith): Highly specific (99%) but less sensitive (25-30%)
• Anti-SSA/Ro (52 and 60 kDa): Associated with photosensitivity, neonatal lupus, and heart block
• Anti-SSB/La: Often co-occurs with anti-SSA/Ro
• Anti-phospholipid antibodies: Include lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I

Laboratory Abnormalities:

• Complement levels: Low C3 (reference: 83-177 mg/dL) and C4 (reference: 15-45 mg/dL) during active disease
• Complete Blood Count: Leukopenia (<4,000/μL), lymphopenia (<1,500/μL), thrombocytopenia (<100,000/μL)
• Urinalysis: Proteinuria (>0.5 g/day), hematuria, cellular casts
• ESR: Typically elevated (>30 mm/hr) while CRP may be normal

SLE Classification Criteria (2019 EULAR/ACR): Requires ANA ≥1:80 and weighted score ≥10 from clinical and immunologic criteria. Key criteria include constitutional symptoms (fever), cutaneous manifestations, arthritis, neuropsychiatric symptoms, serositis, renal involvement, and specific autoantibodies.

Systemic sclerosis (SSc) is characterized by progressive fibrosis, vasculopathy, and autoimmunity affecting skin and internal organs. The disease is classified into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) based on the extent of skin involvement.

Clinical Subtypes and Features:

Limited Cutaneous SSc (lcSSc):

• CREST Syndrome: Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasias
• Skin involvement limited to face, neck, and distal extremities
• Later onset of internal organ involvement
• Better overall prognosis

Diffuse Cutaneous SSc (dcSSc):

• Skin involvement proximal to elbows and knees, including trunk
• Early and severe internal organ involvement
• Rapid progression in first 3-5 years
• Higher mortality rate

Vascular Manifestations:

• Raynaud's Phenomenon: Present in >95% of patients, often the initial symptom
• Digital Ulcers: Result from severe digital ischemia
• Pulmonary Arterial Hypertension: Major cause of mortality, particularly in lcSSc
• Scleroderma Renal Crisis: Acute hypertensive emergency with microangiopathic hemolytic anemia

Autoantibody Profile:

Organ System Involvement:

• Pulmonary: Interstitial lung disease (ILD) in 70% of dcSSc patients, pulmonary arterial hypertension
• Gastrointestinal: Esophageal dysmotility (90%), gastroesophageal reflux, small bowel bacterial overgrowth
• Cardiac: Pericarditis, myocardial fibrosis, conduction abnormalities
• Renal: Scleroderma renal crisis (10-15% of dcSSc patients)

Diagnostic Approach: Diagnosis relies on 2013 ACR/EULAR classification criteria including skin thickening, fingertip lesions, telangiectasias, abnormal nailfold capillaries, pulmonary arterial hypertension or ILD, Raynaud's phenomenon, and SSc-related autoantibodies.

Sjögren's syndrome is a systemic autoimmune disease primarily targeting exocrine glands, resulting in progressive glandular dysfunction and the pathognomonic triad of dry eyes (keratoconjunctivitis sicca), dry mouth (xerostomia), and systemic autoimmune features.

Pathophysiology: The disease involves lymphocytic infiltration of exocrine glands, particularly lacrimal and salivary glands. CD4+ T cells predominate in early stages, followed by B cell proliferation and germinal center formation. This leads to acinar cell destruction, ductal epithelial cell proliferation, and eventual glandular fibrosis.

Clinical Manifestations:

Glandular Features:

• Ocular: Dry eyes, foreign body sensation, photophobia, corneal ulcerations
• Oral: Dry mouth, dental caries, difficulty swallowing, taste alterations
• Other Glandular: Parotid gland enlargement (60%), dry nose, vaginal dryness

Extra-glandular Manifestations:

• Musculoskeletal: Non-erosive arthritis (60%), fibromyalgia
• Pulmonary: Interstitial lung disease, bronchial hyperreactivity
• Renal: Interstitial nephritis, distal renal tubular acidosis
• Neurologic: Peripheral neuropathy (20%), CNS involvement (rare)
• Hematologic: B-cell lymphoma (5-10% lifetime risk)
• Dermatologic: Purpura, cutaneous vasculitis

Laboratory and Diagnostic Findings:

Autoantibody Profile:

• ANA: Positive in 80-90%, typically fine speckled pattern
• Anti-SSA/Ro52: Present in 60-70%, associated with extra-glandular features
• Anti-SSA/Ro60: Present in 50-60%, linked to photosensitivity
• Anti-SSB/La: Present in 40-50%, associated with earlier disease onset
• Rheumatoid Factor: Positive in 60-90% of patients

Objective Tests:

• Schirmer's Test: <5 mm wetting in 5 minutes indicates severe dry eyes
• Ocular Staining Score: Rose Bengal or lissamine green staining of conjunctiva and cornea
• Unstimulated Salivary Flow: <0.1 mL/min indicates severe hyposalivation
• Sialography: Shows ductal dilatation and contrast pooling

Histopathologic Features: Minor salivary gland biopsy showing focus score ≥1 (≥50 lymphocytes per 4 mm² of glandular tissue) is pathognomonic. The infiltrate consists predominantly of CD4+ T cells and B cells organized in germinal center-like structures.

Classification Criteria (2016 ACR-EULAR): Requires weighted score ≥4 from: anti-SSA/Ro positivity (3 points), focal lymphocytic sialadenitis with focus score ≥1 (3 points), ocular staining score ≥5 (1 point), Schirmer's test ≤5 mm/5min (1 point), unstimulated salivary flow ≤0.1 mL/min (1 point).

Systemic vasculitides are a heterogeneous group of autoimmune diseases characterized by inflammatory destruction of blood vessels. Classification is based on vessel size, histopathology, and clinical patterns, with the 2012 Chapel Hill Consensus Conference providing the current nomenclature.

Classification by Vessel Size:

Large Vessel Vasculitis:

• Giant Cell Arteritis (GCA): Temporal arteritis, affects aorta and major branches
• Takayasu Arteritis: Affects aortic arch and major branches, typically young women

Medium Vessel Vasculitis:

• Polyarteritis Nodosa (PAN): Necrotizing arteritis, hepatitis B association
• Kawasaki Disease: Pediatric coronary arteritis

Small Vessel Vasculitis:

ANCA-Associated Vasculitis (AAV):

Anti-Neutrophil Cytoplasmic Antibodies (ANCA):

• c-ANCA (Cytoplasmic): Targets proteinase 3 (PR3), associated with GPA
• p-ANCA (Perinuclear): Targets myeloperoxidase (MPO), associated with MPA and EGPA
• Sensitivity and Specificity: c-ANCA/PR3: 95% specific for GPA; p-ANCA/MPO: 90% specific for MPA

Clinical Syndromes:

Granulomatosis with Polyangiitis (GPA):

• Upper Respiratory Tract: Chronic sinusitis, saddle nose deformity, subglottic stenosis
• Lower Respiratory Tract: Pulmonary nodules, cavitations, alveolar hemorrhage
• Renal: Pauci-immune crescentic glomerulonephritis
• Ocular: Scleritis, orbital pseudotumor

Microscopic Polyangiitis (MPA):

• Pulmonary-Renal Syndrome: Rapidly progressive glomerulonephritis with pulmonary capillaritis
• Absence of Upper Respiratory Involvement: Key differentiating feature from GPA
• Systemic: Peripheral neuropathy, skin involvement

Eosinophilic Granulomatosis with Polyangiitis (EGPA):

• Three Phases: Allergic (asthma, rhinitis), eosinophilic (tissue infiltration), vasculitic
• Asthma: Present in >95% of patients, often severe
• Eosinophilia: Absolute count >1,500/μL or >10% of total WBC
• Neuropathy: Mononeuritis multiplex in 60-70%

Diagnostic Approach: Diagnosis requires integration of clinical features, ANCA testing, histopathology, and imaging. Tissue biopsy remains the gold standard, showing necrotizing inflammation with fibrinoid necrosis. The Birmingham Vasculitis Activity Score (BVAS) is used to assess disease activity and monitor treatment response.

The diagnosis of systemic autoimmune diseases requires a systematic approach integrating clinical presentation, laboratory findings, imaging studies, and histopathology. The complexity of these disorders necessitates understanding of immunologic principles and careful interpretation of autoantibody profiles.

Systematic Diagnostic Approach:

Step 1: Clinical Assessment

• Constitutional Symptoms: Fever, weight loss, fatigue (suggest systemic inflammation)
• Multi-system Involvement: Simultaneous involvement of multiple organs
• Disease Pattern: Relapsing-remitting vs. progressive course
• Demographics: Age, sex, ethnicity (important epidemiologic clues)

Step 2: Laboratory Screening

Initial Laboratory Panel:

• Complete Blood Count: Cytopenias suggest autoimmune etiology
• Comprehensive Metabolic Panel: Renal function, electrolytes
• Inflammatory Markers: ESR, CRP (note: CRP may be normal in SLE)
• Urinalysis: Proteinuria, hematuria, cellular casts
• ANA with Pattern: Screening test for systemic autoimmune disease

ANA Interpretation Guidelines:

ANA Patterns and Associations:

• Homogeneous: dsDNA, histones (SLE, drug-induced lupus)
• Speckled: Extractable nuclear antigens (Sm, SSA/Ro, SSB/La, Scl-70)
• Nucleolar: Scl-70, RNA polymerase III, fibrillarin (systemic sclerosis)
• Centromere: Centromere proteins (limited cutaneous systemic sclerosis)

Step 3: Specific Autoantibody Testing

Disease-Specific Panels:

• SLE Panel: Anti-dsDNA, anti-Sm, anti-SSA/Ro, anti-SSB/La, anti-phospholipid antibodies
• Systemic Sclerosis Panel: Anti-Scl-70, anti-centromere, anti-RNA polymerase III
• Myositis Panel: Anti-Jo-1, anti-Mi-2, anti-SRP, anti-TIF1-γ
• ANCA Testing: c-ANCA/PR3, p-ANCA/MPO for vasculitis

Step 4: Complement Assessment

• C3 and C4 Levels: Low levels indicate immune complex consumption
• CH50 (Total Hemolytic Complement): Functional assessment of complement pathway
• C1q: Low levels may suggest hereditary complement deficiency

Reference Ranges for Key Laboratory Values:

• C3: 83-177 mg/dL (0.83-1.77 g/L)
• C4: 15-45 mg/dL (0.15-0.45 g/L)
• CH50: 60-144 units/mL
• Anti-dsDNA: <30 IU/mL (negative), 30-75 IU/mL (indeterminate), >75 IU/mL (positive)

Step 5: Tissue Confirmation

• Renal Biopsy: Essential for lupus nephritis classification and treatment planning
• Skin Biopsy: Direct immunofluorescence for lupus band test
• Temporal Artery Biopsy: Gold standard for giant cell arteritis diagnosis
• Salivary Gland Biopsy: Focal lymphocytic sialadenitis in Sjögren's syndrome

Integration and Clinical Correlation: Laboratory results must always be interpreted in clinical context. False positives can occur in infections, malignancies, and elderly individuals. Serial monitoring of disease-specific markers (anti-dsDNA, complement levels) helps assess disease activity and treatment response.

The management of systemic autoimmune diseases follows a tiered approach aimed at inducing remission, preventing organ damage, and minimizing treatment toxicity. Therapeutic decisions are guided by disease activity, organ involvement severity, and patient-specific factors including age, comorbidities, and pregnancy status.

General Treatment Principles:

Immunosuppressive Hierarchy:

1. Acute Management: High-dose corticosteroids for severe disease
2. Induction Therapy: Intensive immunosuppression to achieve remission
3. Maintenance Therapy: Long-term, less toxic regimens to prevent relapse
4. Rescue Therapy: Aggressive treatment for refractory or life-threatening disease

Corticosteroid Management:

• High-dose Therapy: Prednisone 1-2 mg/kg/day (max 60-80 mg/day) for severe disease
• Pulse Therapy: Methylprednisolone 1000 mg IV daily × 3 days for life-threatening disease
• Tapering Strategy: Reduce by 10-20% weekly initially, then 2.5-5 mg every 2-4 weeks
• Target: <7.5 mg/day prednisone equivalent for maintenance

Disease-Modifying Agents:

Conventional DMARDs:

• Methotrexate: 15-25 mg weekly, monitor CBC, LFTs, creatinine
• Hydroxychloroquine: 5 mg/kg/day (max 400 mg/day), ophthalmologic screening
• Sulfasalazine: 2-3 g/day divided, monitor CBC
• Leflunomide: 20 mg/day, monitor LFTs, blood pressure

Immunosuppressive Agents:

Biologic Therapies:

• Rituximab: Anti-CD20, for refractory lupus, ANCA-associated vasculitis
• Belimumab: Anti-BAFF, FDA-approved for SLE
• Tocilizumab: Anti-IL-6 receptor, for systemic sclerosis, giant cell arteritis
• Abatacept: CTLA-4-Ig, for refractory cases

Disease-Specific Monitoring:

SLE Monitoring:

• Disease Activity: SLEDAI (SLE Disease Activity Index) scores
• Laboratory: Anti-dsDNA, complement levels (C3, C4), CBC, comprehensive metabolic panel
• Frequency: Every 3-6 months in stable disease, monthly during active disease
• Renal Monitoring: Urinalysis, proteinuria quantification, creatinine

Systemic Sclerosis Monitoring:

• Pulmonary Function: Spirometry, DLCO every 6-12 months
• Cardiac Assessment: Echocardiography for pulmonary hypertension
• Renal Function: Blood pressure monitoring, creatinine, urinalysis
• Gastrointestinal: Symptom assessment, nutritional status

Vasculitis Monitoring:

• Disease Activity: Birmingham Vasculitis Activity Score (BVAS)
• Laboratory: ANCA titers, inflammatory markers, organ function tests
• Imaging: Disease-specific (chest imaging for GPA, vascular imaging for large vessel vasculitis)

Preventive Care:

• Infection Prevention: Pneumococcal, influenza, hepatitis B vaccination
• Bone Health: Calcium, vitamin D supplementation, bisphosphonates for corticosteroid-induced osteoporosis
• Cardiovascular Risk: Lipid management, blood pressure control, antiplatelet therapy where appropriate
• Malignancy Screening: Enhanced surveillance, particularly for lymphoma in Sjögren's syndrome

Treatment Goals:

• Clinical Remission: Absence of disease activity
• Serologic Remission: Normalization of disease-specific biomarkers
• Prevention of Flares: Maintain stable, low disease activity
• Organ Preservation: Prevent irreversible damage
• Quality of Life: Minimize treatment-related toxicity